Samuel J. P. Malkin

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

Stephen C. Bain, Brian Bekker Hansen, Samuel J. P. Malkin et al. · Diabetes Therapy · 2019 · 52 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK

Adie Viljoen, C. S. Hoxer, Pierre Johansen et al. · Diabetes Obesity and Metabolism · 2018 · 44 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

Barnaby Hunt, Samuel J. P. Malkin, Robert Gerald Jan Moes et al. · BMJ Open Diabetes Research & Care · 2019 · 42 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden

Johan Jendle, Maria Ida Buompensiere, Astrid Ledgaard Holm et al. · Diabetes Therapy · 2021 · 39 citations · Full text

Medicine, Internal Medicine, Pharmacoeconomics +17

Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis

B.B. Hansen, Solomon Nuhoho, Sarah Ali et al. · Journal of Medical Economics · 2020 · 35 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17